187 related articles for article (PubMed ID: 23747250)
21. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome.
Brito LP; Lerário AM; Bronstein MD; Soares IC; Mendonca BB; Fragoso MC
J Clin Endocrinol Metab; 2010 Oct; 95(10):E271-9. PubMed ID: 20660043
[TBL] [Abstract][Full Text] [Related]
22. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
23. Glucose intolerance and impaired insulin secretion in pancreas-specific signal transducer and activator of transcription-3 knockout mice are associated with microvascular alterations in the pancreas.
Kostromina E; Gustavsson N; Wang X; Lim CY; Radda GK; Li C; Han W
Endocrinology; 2010 May; 151(5):2050-9. PubMed ID: 20215569
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner.
Pan Y; Wang B; Zheng J; Xiong R; Fan Z; Ye Y; Zhang S; Li Q; Gong F; Wu C; Lin Z; Li X; Pan X
J Cell Mol Med; 2019 Feb; 23(2):1059-1071. PubMed ID: 30461198
[TBL] [Abstract][Full Text] [Related]
25. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
[TBL] [Abstract][Full Text] [Related]
26. LIM-homeodomain transcription factor Isl-1 mediates the effect of leptin on insulin secretion in mice.
Chen J; Fu R; Cui Y; Li YS; Pan JR; Liu JL; Luo HS; Yin JD; Li DF; Cui S
J Biol Chem; 2013 Apr; 288(17):12395-405. PubMed ID: 23504315
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
28. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets.
Picinato MC; Hirata AE; Cipolla-Neto J; Curi R; Carvalho CR; Anhê GF; Carpinelli AR
J Pineal Res; 2008 Jan; 44(1):88-94. PubMed ID: 18078453
[TBL] [Abstract][Full Text] [Related]
29. Altered islet morphology but normal islet secretory function in vitro in a mouse model with microvascular alterations in the pancreas.
Kostromina E; Wang X; Han W
PLoS One; 2013; 8(7):e71277. PubMed ID: 23923060
[TBL] [Abstract][Full Text] [Related]
30. Role of fibroblast growth factor receptor 4 in cancer.
Tang S; Hao Y; Yuan Y; Liu R; Chen Q
Cancer Sci; 2018 Oct; 109(10):3024-3031. PubMed ID: 30070748
[TBL] [Abstract][Full Text] [Related]
31. Inactivation of the dual Bmp/Wnt inhibitor Sostdc1 enhances pancreatic islet function.
Henley KD; Gooding KA; Economides AN; Gannon M
Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E752-61. PubMed ID: 22829579
[TBL] [Abstract][Full Text] [Related]
32. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
[TBL] [Abstract][Full Text] [Related]
33. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
35. The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.
Li Q; Zhao Q; Zhang C; Zhang P; Hu A; Zhang L; Schroder PM; Ma Y; Guo Z; Zhu X; He X
J Physiol Biochem; 2018 May; 74(2):247-260. PubMed ID: 29468415
[TBL] [Abstract][Full Text] [Related]
36. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
Cros J; Moati E; Raffenne J; Hentic O; Svrcek M; de Mestier L; Sbidian E; Guedj N; Bedossa P; Paradis V; Sauvanet A; Panis Y; Ruszniewski P; Couvelard A; Hammel P
Neuroendocrinology; 2016; 103(5):495-9. PubMed ID: 26335532
[TBL] [Abstract][Full Text] [Related]
37. The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction.
Quintanal-Villalonga Á; Ojeda-Márquez L; Marrugal Á; Yagüe P; Ponce-Aix S; Salinas A; Carnero A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Sci Rep; 2018 Feb; 8(1):2394. PubMed ID: 29402970
[TBL] [Abstract][Full Text] [Related]
38. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
39. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
[TBL] [Abstract][Full Text] [Related]
40. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
